Risk factors for the occurrence of ampullary tumors: A case-control study.
alcohol
ampullary tumors
aspirin
cholecystectomy
proton pump inhibitors
risk
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
30
05
2022
accepted:
28
06
2022
pubmed:
28
7
2022
medline:
23
9
2022
entrez:
27
7
2022
Statut:
ppublish
Résumé
The incidence of ampullary tumors is increasing but data on association with an increased exposure to certain risk factors are scanty. To investigate risk and protective factors associated with the occurrence of ampullary tumors and whether these factors differ between ampullary tumors of the intestinal and pancreatobiliary subtypes or between adenomas and carcinomas. The association between a large set of exposome features and ampullary tumors occurrence was investigated in a bi-centric case-control study after ethic committee approval and power calculation. In 223 histologically confirmed patients and 446 controls, previous cholecystectomy (odd ratio [OR] = 2.07; 95% confidence interval [CI] = 1.34-3.20) and proton pump inhibitors use (OR = 1.66; 95% CI = 1.16-2.37) were associated with increased risk of ampullary tumors, aspirin use (OR = 0.57; 95% CI = 0.36-0.90) and light alcohol intake (OR = 0.54; 95% CI = 0.38-0.76) with reduced risk. A previous cholecystectomy was also associated with tumors of intestinal subtype and with both adenomas and carcinomas, and proton pump inhibitors use with adenomas only. Smoking, body mass index, family history of cancers, previous ulcer, diabetes and use of statins, insulin and metformin were not significant factors. This is the first case-control study specifically highlighting factors associated with the occurrence of ampullary tumors. We report factors that are novel and plausible, in keeping with mechanisms described for other gastrointestinal tumors and with potential clinical relevance.
Sections du résumé
BACKGROUND
The incidence of ampullary tumors is increasing but data on association with an increased exposure to certain risk factors are scanty.
OBJECTIVE
To investigate risk and protective factors associated with the occurrence of ampullary tumors and whether these factors differ between ampullary tumors of the intestinal and pancreatobiliary subtypes or between adenomas and carcinomas.
METHODS
The association between a large set of exposome features and ampullary tumors occurrence was investigated in a bi-centric case-control study after ethic committee approval and power calculation.
RESULTS
In 223 histologically confirmed patients and 446 controls, previous cholecystectomy (odd ratio [OR] = 2.07; 95% confidence interval [CI] = 1.34-3.20) and proton pump inhibitors use (OR = 1.66; 95% CI = 1.16-2.37) were associated with increased risk of ampullary tumors, aspirin use (OR = 0.57; 95% CI = 0.36-0.90) and light alcohol intake (OR = 0.54; 95% CI = 0.38-0.76) with reduced risk. A previous cholecystectomy was also associated with tumors of intestinal subtype and with both adenomas and carcinomas, and proton pump inhibitors use with adenomas only. Smoking, body mass index, family history of cancers, previous ulcer, diabetes and use of statins, insulin and metformin were not significant factors.
CONCLUSION
This is the first case-control study specifically highlighting factors associated with the occurrence of ampullary tumors. We report factors that are novel and plausible, in keeping with mechanisms described for other gastrointestinal tumors and with potential clinical relevance.
Identifiants
pubmed: 35894762
doi: 10.1002/ueg2.12281
pmc: PMC9486500
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Insulins
0
Proton Pump Inhibitors
0
Metformin
9100L32L2N
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
730-735Informations de copyright
© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Curr Opin Gastroenterol. 2019 Mar;35(2):107-113
pubmed: 30550381
United European Gastroenterol J. 2022 Sep;10(7):730-735
pubmed: 35894762
World J Gastroenterol. 2014 Aug 7;20(29):10144-50
pubmed: 25110442
J Transl Med. 2022 Jun 15;20(1):272
pubmed: 35705951
Surg Clin North Am. 2019 Apr;99(2):357-367
pubmed: 30846039
Endoscopy. 2021 Apr;53(4):429-448
pubmed: 33728632
Sci Rep. 2019 Sep 3;9(1):12676
pubmed: 31481741
United European Gastroenterol J. 2019 Mar;7(2):250-260
pubmed: 31080610
World J Gastroenterol. 2019 Jun 14;25(22):2706-2719
pubmed: 31235994
Gastroenterology. 2001 Sep;121(3):542-7
pubmed: 11522737
J Clin Med. 2019 Jan 11;8(1):
pubmed: 30641967
Br J Surg. 2004 Dec;91(12):1600-7
pubmed: 15515106
Eur J Surg Oncol. 2021 Jul;47(7):1742-1749
pubmed: 33712346
Ann Oncol. 2020 May;31(5):558-568
pubmed: 32272209
Int J Cancer. 2016 Mar 15;138(6):1401-9
pubmed: 26488896
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1315-8
pubmed: 15894693
Sci Rep. 2017 Oct 12;7(1):13024
pubmed: 29026148
Pancreatology. 2020 Sep;20(6):1149-1154
pubmed: 32800645
Br J Cancer. 1999 Feb;79(3-4):640-4
pubmed: 10027343
Epidemiol Health. 2021;43:e2021011
pubmed: 33541011
J Stud Alcohol Drugs. 2016 Mar;77(2):185-98
pubmed: 26997174
United European Gastroenterol J. 2021 May;9(4):461-468
pubmed: 34529357
J Stud Alcohol Drugs. 2007 Mar;68(2):303-10
pubmed: 17286350
Am J Surg. 2001 Jun;181(6):526-8
pubmed: 11513778